Vertex Pharmaceuticals Incorporated (LON:0QZU)
 416.83
 -3.15 (-0.75%)
  At close: Oct 29, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm) 
 $11.42B
Revenue Growth 
 +10.46%
P/S Ratio 
 9.69
Revenue / Employee 
 $1.87M
Employees 
 6,100
Market Cap 
80.80B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% | 
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% | 
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% | 
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% | 
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Vertex Pharmaceuticals News
- 6 days ago - JEPQ, ADI, VRTX, ORLY: Large Outflows Detected at ETF - Nasdaq
- 7 days ago - Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference - Business Wire
- 8 days ago - Insiders Bullish on Certain Holdings of JDOC - Nasdaq
- 8 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
- 9 days ago - ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE - Seeking Alpha
- 13 days ago - Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment - GuruFocus
- 13 days ago - Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic - GuruFocus
- 13 days ago - Vertex IgA nephropathy asset povetacicept granted FDA rolling review - Seeking Alpha